Cosmo Pharmaceuticals NV (XSWX:COPN) Total Current Assets : CHF277.4 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cosmo Pharmaceuticals NV's total current assets for the quarter that ended in Jun. 2023 was CHF277.4 Mil.

Cosmo Pharmaceuticals NV Total Current Assets Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Total Current Assets Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

422.23

330.12

273.29

287.07

302.08

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Current Assets	Get a 7-Day Free Trial															261.63	287.07	279.41	302.08	277.38

Cosmo Pharmaceuticals NV Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cosmo Pharmaceuticals NV's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	237.788	+	38.105	+	11.347	+	14.836
	=	302.1

Cosmo Pharmaceuticals NV's Total Current Assets for the quarter that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	216.641	+	38.44	+	13.122	+	9.178
	=	277.4

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cosmo Pharmaceuticals NV (XSWX:COPN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cosmo Pharmaceuticals NV's Liquidation Value for the quarter that ended in Jun. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	216.641	-	291.345	+	0.75 * 28.55	+	0.5 * 13.122
=	-46.7

Cosmo Pharmaceuticals NV Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines